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“It is not the most intellectual of the species that survives; it is not the strongest that survives; but the 
species that survives is the one that is able best to adapt and adjust to the changing environment in 
which it finds itself.” 
 
Leon C. Megginson. 
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ABSTRACT 
Inflammation is a homeostatically fundamental feature of the host defence surveillance 
system made up of an army of sentinel cells that guard against foreign intrusion. At the 
onslaught of an attack, primary immune responders (macrophages and neutrophils) secrete a 
plethora of cytokines and chemokines that attract secondary responders (T and B cells) to the 
site of inflammation, to eliminate the intrusion and encourage tissue healing. The acute 
inflammatory stimulation is rapidly attenuated following tissue repair to prevent 
hypercytokinemia. However, the dysregulation of inflammatory stimulation can also lead to a 
chronic, erroneous attack on the host immune system, leading to autoimmune diseases and in 
some cases, cancer initiation. The chronic inflammation theory established by Rudolf 
Virchow in 1845 is perhaps the first that accurately described the inflammation-induced 
cancer phenomenon. Since the advancement of technologies, independent researchers have 
brought forth increasing novel evidence to support the role of inflammation in tumorigenesis. 
In the compilation of this thesis, we will explore the multi-faceted role of Angiopoietin-like 4 
(ANGPTL4) in the regulation of the chemokine landscape during both acute and chronic 
inflammation.  
In Part I, we shall investigate the role of ANGPTL4 in attenuating acute inflammation 
through the intermediate tristetraprolin (TTP). We show that ANGPTL4 deficiency resulted 
in an exacerbated inflammatory response in mice subjected to pro-inflammatory stimulation. 
Confirming the current paradigm, we also reveal that significant microbial divergence was 
only visible during inflammation and not at steady states. Using immortalized colonic 
epithelial cells, we connected ANGPTL4 and TTP in the inflammatory signaling axis, and 
show that ANGPTL4 is able to regulate the acute inflammatory landscape through both TTP- 
dependent and independent signaling pathways.  
In Parts II and III, we demonstrate that ANGPTL4 regulates oxidative stress levels in the 
tumor and tumor microenvironment during chronic inflammation, and induces the epithelial-
mesenchymal transition (EMT) process. Capitalizing on numerous cultures like A5RT3, 
MKN78 and HSC5, we first establish that TAK1 protected cells against TGFβ-induced EMT. 
TAK1 deficiency also promoted Rac1-Nox1 activation, increasing overall ROS production 
and augmented mesenchymal markers like Snai1 and E-cadherin. H2O2 augmented key 
signaling intermediates which are involved in cellular homeostasis and increased the 
invasiveness of epithelial cells. In addition, H2O2 also desensitized cells towards TGFβ 
stimulation by decreasing Smad3 and TAK1 expression. To underscore the medical relevance 
of ANGPTL4 in tumorigenesis, we reveal that ANGPTL4 drives EMT by elevating cellular 
energy flux through 14-3-3γ. In addition, 14-3-3γ promotes the transcription of E-cadherin by 
stabilizing the binding of Snai1 to its promoter during EMT.  
These findings illustrate the importance of ANGPTL4 in regulating the inflammatory 
landscape during both acute and chronic inflammation, and in tumorigenesis, expanding its 
role outside of metabolism, insulin resistance, angiogenesis and wound healing. 
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1.1 THE GASTROINTESTINAL TRACT: FUNCTION AND DEFENCE 
An estimated 10
14
 microorganisms make up the human flora, comprising of more than 10 000 
bacterial species altogether [1, 2]. Hence, it is critical that we distinguish and recognize both 
specific microbes, metabolites and genes in the collection of microbiome that confer health 
benefits to its host [3, 4]. To date, the exact composition that makes up the microbiota of a 
healthy individual remains unknown. Scientists estimate that about 300 – 1000 microbial 
species make up the microflora in the entire gastrointestinal tract. In addition, the lower 
gastrointestinal tract including both the small and large intestine was found to contain the 
largest reservoir of intestinal microflora. Microbes residing along the human gastrointestinal 
tract exhibit habitat-specific traits. To date, studies suggest that more than 99% of the total 
microbiota in the gastrointestinal tract consists of anaerobic bacteria, while only those 
residing in the caecum are believed to be predominantly aerobic [5]. For instance, microbial 
species representing Bacteroides, Clostridium, Fusobacterium, Eubacterium, Ruminococcus, 
Peptococcus, Peptostreptococcus, and Bifidobacterium are amongst the most common 
microbial genera present in the lower gastrointestinal tract of a normal healthy individual [5-
8]. 
Intestinal epithelial cells (IECs) lining the gastrointestinal tract play an important role as a 
physical barrier to prevent the invasion of bacteria to the host lamina propria. Hence, the 
presence of a dynamic and viable intestinal immune system as the first line of defence, allows 
for a balanced homeostasis between the host and the microbiota community, and in turn, the 
disregulation of the system, leads to diseases. Although the morphology of the small intestine 
and the colon differs, the host innate immune approach consists of 2 main strategies: to keep 
the integrity of the gastrointestinal wall through the continuous production of mucus; and the 
secretion of antimicrobial peptides (AMPs) by underlying immune and epithelial cells in the 
lamina propria and submucosa (Figure 1.1).  
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Figure 1.1 The immune landscape in the gastrointestinal tract. A monolayer of intestinal epithelial 
cells (IECs) acts as a barrier that partitions the host cells in the lamina propria and the resident 
microflora in the intestinal lumen. IECs in the colon (colonocytes) and the small intestine 
(enterocytes) play roles in absorption of water and nutrients respectively. Enteroendocrine and 
Paneth cells secrete enteric hormones and antimicrobial peptides respectively. Located in proximity 
with the Paneth cells, epithelial stem cells reside in the crypt regions divide to give daughter cells, 
which later differentiate into mature IECs as they move towards the luminal surface. Other immune 
cells like T cells, B cells, dendritic cells and resident macrophages also reside under the lamina 
propria located close to the IECs. Peyer’s patches consisting of lymphatic tissues are also found 
throughout the ileum, and are primarily responsible for monitoring intestinal bacterial load. 
Modified and reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology. 
Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes 
intestinal function. Nat Rev Immunol. 10(2):131-144. Copyright 2010. 
 
In the colon, goblet cells are the specialized IECs that keep the resident community of 
microbiota at bay. Goblet cells residing amongst colonocytes mainly produce mucin-2 
protein, which are the building blocks for the mucus matrix [9]. The colon is coated with a 
double layer of mucus – an inner, stratified layer of mucus in proximity with the epithelial 
apical surface, as well as an outer, non-attached mucus layer that is in contact with the lumen. 
Mucin glycans found in the matrix of the outer mucus layer also act as a nutrient supply for 
resident microbiota. In turn, by-products of microbial fermentation like short chain fatty acids 
(SCFAs) are absorbed by colonocytes as additional energy source for the host. Because the 
colon is home to more than 10
12
 bacteria per gram of faeces, it becomes of utmost importance 
that the mucus barrier remains intact to limit events of direct contact between host 
colonocytes and the gut microbiota. In contrast, the small intestinal mucus layer has been 
found to be discontinuous because enterocytes are primarily responsible for nutrient 
absorption and must be in contact with the luminal space [9]. To avert possible assaults, 
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Paneth cells located close to the crypt region of the small intestine secrete AMPs like 
defensins and lectins to form a biochemical barrier in place of the lack of a continuous mucus 
barrier [10, 11] while other host plasma cells secrete immunoglobins (i.e. IgA) [12]. Although 
once considered to be commensal, the prokaryotic resident microbiota can trigger an 
inflammatory response and poses severe health risks to its host once the gastrointestinal 
barrier is breached. Microbes that are capable of degrading mucin-2 and its related glycans 
can weaken the mucus matrix and hence, reside and grow in proximity with the host 
epithelial cells. 
 
1.1.1.1 The Benefits and Hindrance of Host-Microbiota Interactions in the GI tract 
In humans, only about 85% of all dietary carbohydrates are absorbed in the proximal small 
intestine [13, 14]. Indigestible carbohydrates, short chain fatty acids (SCFAs), and 
polysaccharides representing about 25% of the total ingested energy enter the distal small 
intestine and colon [15, 16]. Without the fermentation action of colonic microbes, this form 
of energy would have remained inaccessible to the host. The fermentation process of colonic 
microbes causes the breakdown of large carbohydrates and dietary fibers to give SCFAs like 
acetate, propionate and butyrate [17], which can then bind to G-protein coupled receptors 
(GPRs) to regulate a variety of downstream processes [18, 19], or be directly utilized as a 
source of energy by the host (Figure 1.2).  
Numerous studies have implicated a continuous interplay between the microbiota residing in 
the gastrointestinal tract and various host functions. A stable gut microbial landscape 
resembles a form of defence system because it reduces the risks of pathogenic invasion 
through competitive exclusion [1]. Commensal microbes have been reported to be involved 
in the normal development of the gut and also control systemic functions including 
development, immunity and metabolism in the host [6, 20]. In addition to secreting digestive 
enzymes, gut microbes are essential for the production of SCFAs through fermentation of 
dietary fibres [21]. SCFAs like acetate, propionate and butyrate also play an integral 
component of intestinal energy balance and defence [22] (Figure 1.3). 
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Figure 1.2 Regulation of intestinal microflora on host energy metabolism. If not for intestinal 
micrbiota, about 30% worth of the total dietary energy cannot be harvested because the host 
digestive system cannot break down complex polysaccharides and carbohydrates. The fermentation 
process by intestinal microbiota gives rise to SCFAs which can be utilized by the host. SCFAs 
positively regulate GPR 41/43 receptors to increase fermentation. The regulation of ANGPTL4 (FIAF) 
in intestinal epithelial cells also mediates LPL activity, which alters fat deposition and accumulation in 
surrounding adipocytes. Reprinted from Nutr Clin Pract., Rosa Krajmalnik-Brown et al, Effects of gut 
microbes on nutrient absorption and energy regulation, 2012 Apr; 27(2): 201–214, Copyright 2012, 
with permission from SAGE Publications.  
 
Different members of SCFAs have also been reported to contribute to unique host 
homeostatic processes that might be both tissue and species specific. The binding affinities 
between SCFAs are also unique to specific GPRs. For example, it was previously 
demonstrated that GPR109A is highly selectively for only butyrate [23], while GPR43 binds 
acetate and propionate over butyrate and GPR41 binds propionate and butyrate over acetate 
[24, 25]. Perhaps of all multivariate roles of SCFAs, the anti-inflammatory action of butyrate 
has most widely been associated with its selectivity and specificity as a potent, non-
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competitive histone deacetylase (HDAC) inhibitor [26].  Butyrate has been reported to 
mediate the crosstalk between the gut microbiota and host diseases like colitis [27], type II 
diabetes and obesity [28] through epigenetic regulation and also energy homeostasis through 
GPR41 [29]. On the other hand, acetate and propionate has been reported to regulate other 
processes like adipose-specific insulin signaling [30, 31] via GPR43. In a recent study 
conducted by Ang A et al., acetate was demonstrated to decrease the expression of 
inflammatory cytokines by increasing p38 phosphorylation and repressing the 
phosphorylation of AKT and ERK2 in human monocytes [32]. Interestingly, only an increase 
in p38 and not AKT or ERK2 phosphorylation was observed when mouse monocytes were 
treated with acetate. Although more studies are needed to show if this acetate/GPR43/41 
signaling cascade is unique to monocytes or if it also applies to other cell types or host 
processes, this monocyte acetate-dependent inflammatory response has been demonstrated to 
be species-specific.  
 
Figure 1.3 The impact and distribution of short chain fatty acids (SCFAs) on host homeostatic 
processes. The lumen of the gastrointestinal tract is one of the primary sites of SCFA production. As 
nutrients are absorbed by the epithelial cells and channeled away into the circulation, the 
concentration of SCFAs reduces. SCFAs are believed to play important roles in regulating host 
metabolism and immunity. Modified from Gut Microbes, Douglas J. Morrison and Tom Preston. 
Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism, 
2016; 7(3): 189-200. Copyright The Author(s); permitting unrestricted use, distribution and 
reproduction.  
 
Microbes residing in the colonic mucosa can regulate the levels of epithelial ANGPTL4 [33, 
34], while others suggest that ANGPTL4 is a downstream target of GPR 41/43 activation [22, 
35]. The regulation of ANGPTL4 alters lipoprotein lipase (LPL) activity in the 
gastrointestinal tract, directly affecting lipogenesis and the amount of fat deposition and 
accumulation in circulation, as well as in other storage organs like adipocytes, liver and 
skeletal muscles. Adipocytes also secrete hormones like adiponectin and leptin in response to 
changes in SCFA levels. Leptin regulates satiety and appetite in the arcuate nucleus region of 
the hippocampus [36, 37] (opposed by ghrelin) while adiponectin activates AMP to AMPK to 
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stimulate cellular fatty acid oxidation [38, 39]. Activated by GPR41/43, the secretion of 
peptide YY (PYY) also reduces peristalsis and gut motility, allowing for increased nutrient 
absorption [40, 41]. Current studies underscored a significant role for commensal gut 
microbes in energy regulation, the unwanted enrichment of a subset of microbes can lead to 
excess energy harvest and storage [42, 43] that contribute to the development of various 
facets of the metabolic syndrome [44, 45]. Current metabolomics findings revealed that 
obesity is associated with an enrichment of microbes belonging to Actinobacteria and 
Firmicutes, while decreased fat storage (leanness) has been correlated to the enrichment of 
Bacteroidetes population [43]. Indeed, genetically obese (ob/ob) mice on normal chow diet 
demonstrated an increase in Firmicutes:Bacteroidetes population ratios [46]. However, the 
cause and effect remains to be determined; it is unclear if the state of obesity selects for 
Firmicutes population or if a stable population of Firmicutes in the gastrointestinal tract 
results in inevitable obesity [47].  
Despite great mutualistic benefits between microbiota in the gastrointestinal tract and its 
hosts, it is important to note that these microbes can also become opportunistic pathogens 
(Figure 1.4). Some famous examples of bacterial-induced inflammation of the 
gastrointestinal tract (gastroenteritis) include inflammatory bowel disease (IBD). Ulcerative 
Colitis and Crohn’s Disease are well characterized IBDs whereby the commensal gut 
microbiota in the gastrointestinal tract invade host epithelial cells, causing inflammation 
predominantly in the ileum and/or the colon which might potentially progress to give 
colorectal cancer [48]. On the other hand, cholera involves the colonization of Vibrio cholera 
and infection to the small intestine [49]. A seemingly mild infection by Helicobacter pylori 
can bring about ulcer formation in the stomach and duodenum. However, H. pylori also 
secrete a cocktail of enzymes and proteases which further injures epithelial cells, leading to 
the development of gastric cancer [50]. 
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Figure 1.4 An intact and continuous epithelial barrier supports healthy gastrointestinal 
homeostasis. In a healthy gut environment, cells lining the gastrointestinal wall continuously secrete 
mucus and anti-microbial peptides (AMPs). Not only does the mucus layer form a physical barrier to 
keep gut microbiota at bay, it acts as a matrix layer that also allows for a unique habitat for the 
selection and colonization of commensal gut bacteria. Anti-microbial peptides are secreted by a 
variety of immune cells located further away in the submucosa and the lamina propria, creating a 
tolerant immune environment made up of a unique balance of both pro- and anti- inflammatory 
chemokines. However, a disregulation of mucus or AMP production disrupts healthy gut 
homeostasis. The lack of a physical compartmentalization of the host from the plethora of gut 
microbes allows the invasion of opportunistic pathogens. In response to the onslaught, immune cells 
secrete large amounts of pro-inflammatory chemokines to launch an immune attack against invading 
pathogens, causing a dysregulated immune envioronment. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Immunology. Brown EM et al. The role of the immune system in governing 
host-microbe interactions in the intestine. Nat Immunol. 14(7): 660-667. Copyright 2013. 
 
IECs and a subset of immune cells express protein recognition receptors (PRRs) which aid in 
monitoring the bacterial load and maintaining healthy intestinal homeostasis [51]. The major 
PRRs are the Toll-like receptors (TLRs), as well as the nuclear oligomerization domain-like 
receptors (NOD-like receptors or NLRs). PRRs recognise microbe-associated molecular 
patterns (MAMPs), which consists of a wide variety of bacterial-related components like 
peptidoglycans, lipopolysaccharides and microbial RNA/DNA [52]. 
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1.1.1.2 Effects of Development and Lifestyle Adaptations on Microbiota Variability 
Research suggests changes in the landscape of microbiota in the gastrointestinal tract are also 
simultaneously observed over the course of development. Currently, 2 distinct milestones 
during human development – namely, birth and weaning, have observed significant change in 
the composition of the microbiota in the gastrointestinal tract. While the gastrointestinal tract 
of the foetus within the womb is thought to be almost sterile, newborns acquire microflora 
immediately following birth through contact with the mother and also from the surrounding 
environment. At the outset of birth, infants are believed to first be colonized by facultative 
anaerobes such as Enterococcus, Streptococcus, Staphylococcus and Enterobacter spp, and 
thus, creating a reducing environment conducive for the subsequent colonization of strict 
anaerobic microbes like Bacteroides and Clostridium spp [53, 54]. Although the intestinal 
microbiota ecosystem is believed to be stabilized up to three years after birth, reports suggest 
that the various methods of childbirth contributes significantly to the rate of gut microbiota 
colonization [55, 56]. During weaning, facultative anaerobes has been observed to give way 
to obligate anaerobes [2]. As such, the dominant mode of energy synthesis in the gut 
microbiota switches from aerobic respiration to anaerobic fermentation. Although commensal 
gut microbiota has been identified to be unique between males and females, little was known 
about its function on host development. Recent research shows that alterations in the 
composition of gut microbiota modify the levels of circulating testosterone in males and 
females to a different extent. This implies that an active crosstalk is present between gut 
microbiota and host development even in adults [57]. This results in the production of a 
different landscape of metabolites, which in turn is believed to affect host metabolism. 
Consensus accredits the composition of microbiota in the gastrointestinal tract to be 
predominantly dependent on the lifestyle of the host. For instance, the use of antibiotics 
during treatment has been observed to alter the microbial ecosystem along the gastrointestinal 
tract [58]. Recent studies have shown that the reduction of commensal bacteria in the 
gastrointestinal tract through excessive use of antibiotics in early life increases the risks of 
developing inflammatory bowel disease and asthma [59]. Strikingly, it has come to attention 
that the diet could potentially also modify the components of the flora in the gastrointestinal 
tract. While diet containing high amounts of carbohydrates select for Prevotella species of 
microbes, diet with high amounts of proteins and fats will favor Bacteroides species. Since 
the gut microbiota is impermanent and fluid, a change in diet is likely to modify the 
ecosystem of microbes living in the gastrointestinal tract [60]. 
 
1.1.1.3  Gnotobiotic Animals 
With the advancement of technology, many groups embarked on independent journeys to 
study the symbiotic relationship between commensal microbiota and its host. As such, 
independent groups tried to create the first gnotobiotic model. When the use of antibiotics did 
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not successfully eradicate the entire profile of microbes, scientists utilized new technologies 
that kept animals germ free.  
Presumably pioneered by James Reyniers in 1920 [61], germ-free (GF) animals are often 
used as tools for proof-of-concept trials and were popular in fields like microbiology [43]. 
However, scientists soon realize that because GF animals had under-developed immune 
systems, GF mice were more susceptible to pathogenic infections when compared with 
specific-pathogen-free (SPF) mice that were raised in normal conditions [62]. As interests to 
understand the plasticity of commensal microbiota grew, attention was drawn to the lower 
gastrointestinal tract because the ileum and colon harbors the highest density of microbes [5-
8]. To date, evidence suggests that neonatal microbial exposure is crucial in the development 
of the brain [63] and immune system [64], as well as the membrane barriers of the testis [65] 
and the blood brain barrier [66]. In addition, recent data indicates that the intestinal 
microflora might play roles in energy harvest [33, 67], and in modulating neuronal signaling 
cascades that govern behavior and motor control [68].  
In recent years, the increasing interests of characterizing GF mice also highlight the 
importance of PRRs- microbiota associations. GF mice exhibited an under-developed 
immune system [69]. GF mice lacked immune-associated structures like lymphoid follicles 
and Peyer’s patches in the small intestine [70]. They exhibited an immature and under-
developed gastrointestinal tract lacking proper mucus formation [71, 72]. In addition, the 
removal of an important downstream target of TLR signalling, MyD88, saw a decreased 
response towards inflammatory signals like IL-18 and IL-1β [73], and reduced intestinal 
lymphocytes [74]. PRR-MAMP complexes also support and boost the production of 
glycoproteins in the mucus matrix, hence maintaining the integrity of the mucosal barrier 
[75]. 
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1.2 INFLAMMATION 
Inflammation is a fundamental, homeostatic role of the host defence system. It usually 
categorised by the cause and mechanism, and can be further divided into the severity 
(intensity) or eventual outcome. The early surveillance system is made up of an army of 
immune sentinel cells that alert the host of the intrusion of foreign particles in the body 
during acute inflammation events. Primary immune cell responders secrete a variety of 
cytokines and chemokines that attract other specialized immune cells like macrophages, 
neutrophils, T- and B-cells to combat and eliminate the intrusion – mechanical or microbial – 
and to encourage healing of surrounding tissues. As the wound repair, the inflammation is 
gradually resolved.  Thus, a timed and balanced secretion of both anti- and pro-inflammatory 
cytokines allow for the rapid initiation and attenuation of inflammatory responses. Chronic 
inflammation occurs when the inflammation signals continue to persist even after the removal 
of foreign particles. In these less well-defined events, the sustained secretion of pro-
inflammatory cytokines and chemokines continue to attract immune cells to the presumed 
site-of-injury, culminating in tissue-damaging cytokine storm, or hypercytokinemia. 
In retrospect, the inflammatory bowel disease (IBD) is one of the well-documented 
microbial-associated, chronic inflammatory events in the gastrointestinal tract. The epithelial 
cells that line the gastrointestinal tract serve as a physical barrier that separates the host from 
its surrounding microbiota, nonetheless, they are in close proximity with environmental and 
dietary carcinogens. It was reported that the increase activation of CD8
+
 cells coupled with 
the elevation in ROS production, or KRAS and TP53 mutations aggravate chronic IBD-
related inflammation, supporting a close link to colorectal cancer initiation and progression 
[76-79]. Recent studies demonstrate that microbial infections also pose significant cancer 
risks [80]. For instance, Helicobacter pylori (gram negative) and Streptococcus bovis (gram 
positive) are bacteria that have been associated with gastric and colon cancers. Some viruses 
have also been shown to cause host DNA mutations by inserting its DNA or RNA into the 
host cell in attempts for replication. For example, the Epstein-Barr virus (belonging to the 
family of herpes virus) has been documented to increase the risks to developing lymphoma 
while certain strains of the human papilloma group of viruses have been linked to the 
development of cervical cancer. Hepatitis B/C viruses are also correlated to increased risks of 
developing liver cancer and the human immunodeficiency virus causes the acquired immune-
deficiency syndrome (AIDS), which does not cause cancer directly but weakens the immune 
system of the infected, ultimately elevating the risk of developing other types of cancers or 
diseases. 
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1.2.1 Tristetraprolin (TTP) in Acute Inflammation 
The role of TTP in acute inflammation was first identified when the embryonically non-lethal 
mouse deficient of TTP developed progressive manifestations autoimmune, inflammatory 
responses like erosive arthritis, dermatitis, cachexia and eventually high titers of antinuclear 
antibodies [81]. Subsequently, it was demonstrated that TTP is involved in the formation of a 
negative feedback loop responsible of modulating the production of TNF-α by destabilizing 
its mRNA transcripts [82]. Further studies showed that the removal of the TTP-binding 
region in the 3’ UTR of TNF-α was sufficient to cause inflammatory arthritis [83]. TTP binds 
to the AREs located at the 3’ UTR of TNF-α [84] and initiate deadenlyation [85], initiates 
deadenlyation to destabilize mRNA transcripts and target them for degradation [82, 86]. 
Subsequent findings have identified that TTP also targets other pro-inflammatory and cell 
cycle proteins [87] like CCL2 [88], c-myc [89], IFN-γ [90] and iNOS [91].  
The transcription factor NF-κB is positively regulated by TNF-α and is considered to be a 
prototypical pro-inflammatory signaling pathway [92]. Functionally active NF-κB exists as 
either a hetero- or homo-dimer, made up from the combination of Rel A (p65), Rel B, Rel (c-
Rel), NF-κB1 (p50 and p105 precursor) and NF-κB2 (p52 and p100 precursor) [93]. The 
most abundant p65/p50 heterodimer combination is usually sequestered in its inactive state 
by binding to cytosolic IκB complexes [94].  Pro-inflammatory stimuli activate the IκB 
kinase (IKK) complex. Consisting of 3 catalytic subunits, IKKα, IKKβ and IKKγ, IKK 
phosphorylates IκB (IκBα subunit) and targets it for degradation [95] and leading to the 
dissociation of the IκB-NF-κB inhibitory complex [96]. This unmasks the nuclear 
locatlization signal on NF-κB, allowing its nuclear translocation to regulate the transcription 
of a plethora of pro- and anti-inflammatory target genes engaged in immune modulation [97]. 
Observations from independent groups indicate that cytosolic TTP is able to bind and prevent 
the nuclear import of the NF-κB p65 subunit [98, 99], providing an alternative function of 
TTP exclusive of its mRNA destabilization activity.  Put together, these evidences are 
consistent with previous postulations [82] that suggest that TTP might have further inhibitory 
effects on the transcription of a subset of inflammatory-related genes. 
 
1.2.1.1 Expression and Regulation of TTP 
Tristetraprolin (TTP), also known as zinc finger protein 36 homolog (ZFP36), Nup475 or 
GOS24, belongs to a family of proteins containing the CCCH (CX8CX5CX3H) tandem 
repeats. TTP was first identified by two independent groups in 1990 using the adipocyte-like, 
mouse 3T3-L1 cells [100, 101]. TTP has two exons and one intron. Currently, there are four 
known isoforms of TTP: ZFP36, ZFP36-like 1 (ZFP36L1), ZFP36-like 2 (ZFP36L2) and 
ZFP36-like 3 (ZFP36L3). Most mammals express three of four TTP isoforms (ZFP36, 
ZFP36L1 and ZFP36L2) while ZFP36L3 is expressed only in the placenta of rodents [102]. 
The mouse TTP gene is located on chromosome 7 encoding for a 319-amino acid long 
protein while the human TTP gene is located on chromosome 19, translating into a 326-
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amino acid long homologue. TTP proteins exist in low levels in non-stimulated cells, 
predominantly in the nucleus in its unphosphorylated state. Upon stimulation, TTP 
translocates into the cytoplasm and bind the Adenosine-Uridine rich elements (AU-rich 
elements, AREs) located at the 3’UTR of target mRNAs [103] (Figure 1.5). The formation of 
translationally repressed mRNA (translational repression complex) gives rise to two primary 
forms of mRNA degradation: 3’ to 5’ decay through exosome complexes or 5’ to 3’ decay 
through processing bodies.   
 
Figure 1.5 Regulation of chemokines by Tristetraprolin. The activity of TTP is an outcome of a 
balance between PP2A and MK2. p38 MAPK-MK2 dependent signaling causes the phosphorylation of 
TTP and recruits 14-3-3 complex, sequestering the activity of TTP in the cytosol. On the contrary, 
PP2A inhibits the action of MK2, resulting in the unphosphorylation of TTP. This allows TTP to 
recognize and bind the AREs of target mRNAs. This process first triggers deadenylation and the 
formation of translational repression complexes and the eventual degradation of target chemokines. 
mRNA degradation happens predominantly through the exosomes (3’ to 5’ decay) and the 
processing bodies (p-bodies; 5’ to 3’ decay).  
 
Gathering work on TTP revealed that transcription factors and other molecules like SP1, 
AP2, NF-κB, EGR1, TPE1 and ELK1 can transcriptionally regulate the expression of TTP 
[104, 105]. TTP was initially identified as an acute-response gene because of its rapid 
induction towards stimuli like insulin, serum as well as other known mitotic agents like TGF-
α and p38 MAPK [87, 100, 106-108].  
Several serine residues have been found to be phosphorylated in the active form of TTP. 
Subsequently, TTP has been reported to be stimulated by p38 MAPK and later 
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phosphorylated by the mitogen-activated protein kinase-activated protein kinase 2 (MK2) 
[109] at S60 and S186 in human and S52 and S178 in mouse [87]. However, whether 
phosphorylated TTP displayed altered ARE-binding capability remains unclear [109]. 
Interestingly, phosphorylated TTP recruits 14-3-3 adaptor proteins, which reduces the 
degradation activity of TTP and allowing for downstream chemokine stabilization [110, 111]. 
The protein phosphotase 2A (PP2A) has been identified to be antagonistic towards MK2 
activity, dephosphorylating TTP and causing the degradation of mRNA [110, 112]. 
 
1.2.1.2 mRNA Transcript Stability and its Impact on Immunosuppression 
The balance between target mRNA destabilization and stabilization depends on the ratio of 
the different cellular regulators present in its environment. In contrast to TTP, the human 
antigen R (HuR) protein, competes for binding at the ARE of the 3’ UTR region of target 
mRNA transcripts, stabilizing and putting a stop to mRNA degradation [113, 114]. Human 
HuR is encoded for by the ELAVL1 gene, is thus, a positive regulator of mRNA stabilization 
and gene expression [115]. Although much remains to be investigated, it was reported that 
HuR plays imperative roles in the transcriptional regulation of mRNA transcripts involved in 
microRNA regulation [116], immune response [117, 118], cancer [119, 120], as well as virus 
replication [121]. Recently, it was reported that HuR is detrimental in positively regulating 
the translation of TNF precursors and protein expression into functional TNF-α [122]. 
The dysregulation or overexpression of pro-inflammatory chemokines and cytokines, i.e. a 
chemokine storm more commonly known as hypercytokinemia, leads to erroneous damage 
on the host tissue [123]. Immunosuppressive drugs have been used to rein the hyperactivation 
of the host immune system. Immunosuppressive drugs are classified into 5 categories: 
cytostatics, antibodies, anti-immunophilins, glucocorticoids, and other drugs that target active 
components of the innate immune system. Cytostatics affect the proliferation of B and T cells 
and largely inhibit cell division [124]. Antibodies are sometimes used as quick-response 
agents to quench the immune response [125, 126]. The use of drugs against immunophilins 
are targeted at the inhibition of prolyl isomerise to prevent the interconversion between the 
cis and trans position of peptidyl-prolyl groups [127]. Glucocorticoids are arguably the most 
extensively used immunosuppressant to date [128]. Glucocorticoids inhibit a wide assortment 
of interleukins [129] and chemokines [128, 130], as well as decreasing eicosanoid and 
cyclooxygenase (COX-1/2) synthesis and expression [131, 132]. Interestingly, 
glucocorticoids have been observed to positively regulate MKP-1 (also recognised as 
DUSP1) [133-135], which has shown to increase the activity of TTP-dependent 
destabilization of pro-inflammatory cytokines [136-138]. 
1.2.2 Oxidative Stress in Chronic Inflammation and Cancer 
The rapid development and advancement of technology over the last century fueled novel 
research techniques that supported Rudolf Virchow’s ‘chronic irritation theory’. In 1845, 
Virchow coined the term leukemia when he reported significant elevation of white blood 
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cells in patients. Subsequently, he demonstrated that normal cells can become neoplastic to 
give rise to cancers [139], and described the cancer initiation and propagation as a result of 
tissues under sources of severe irritation that spread through a liquid medium. Virchow also 
described that cancers were intrinsically related to white blood cells which were the original 
cause of this irritation, an observable fact we now relate to as tumor-associated macrophages 
during inflammation [140-142]. In subsequent breakthrough findings, Katsusaburo 
Yamagiwa et al demonstrated the role of chemical carcinogens in cancer [143] while Francis 
Peyton Rous et al established the existence of cancer-causing viruses [144]. Scientists then 
discovered a cluster of genes that regulated cellular growth (proto-oncogenes that are mutated 
to give oncogenes) as well as the cellular DNA repair mechanism (tumor suppressor genes). 
Researchers also hypothesized the two-hit hypothesis (also known as the Knudson 
hypothesis), which suggests that multiple hits were required to induce cancer. In this respect, 
the term field cancerization becomes an extension of the two-hit hypothesis because an earlier 
hit increases the predisposition of the cells in the cancer vicinity to developing a larger tumor.   
Numerous mechanisms by which chemical carcinogens caused tumorigenesis have been 
proposed [145, 146]. One common underlying theme is the production of free radicals, such 
as reactive oxygen (ROS) and reactive nitrogen species (RNS) [147]. Because of their highly 
reactive nature, the balance between the production of ROS and their elimination by 
antioxidants is important for tissue homeostasis. It is now well-established that low 
concentrations of these reactive species served as signalling mediators [148, 149]. However, 
ROS imbalance or the loss of homeostatic control in a continued oxidative microenvironment 
can either result in cell death caused by oxidative catastrophe or contribute to carcinogenesis, 
which are tissue- and context-dependent. Environmental factors like heightened background 
radiation and pollutant levels in cities, or increase intake of drugs and xenobiotics also 
increases the exposure to exogenous ROS/RNS. Endogenous sources of ROS/RNS are 
generated by essential biological processes such as respiration and inflammation. During 
respiration, free electrons are transported from one membrane-bound donor protein to its 
successive recipients arranged in progressively lower energy levels along the electron 
transport chain to create a proton gradient during mitochondrial respiration and ATP 
synthesis. Under normal homeostatic conditions, oxygen is completely reduced to water at 
the end of the respiratory cycle. However, incomplete reduction of molecular oxygen leads to 
the formation of the superoxide radical (O2
-
), a regular precursor of most other ROS. In its 
protonated form, hydroperoxyl (HO2
-
) has been shown to inactivate enzymes and accelerate 
lipid peroxidation [150, 151]. The dismutation of O2
- 
gives rise to hydrogen peroxide (H2O2), 
and may further be partially reduced to give the hydroxyl radical (OH
-
).  
In normal cells, oxidative stress conjures protective antioxidant response from tissues to 
regain homeostasis. Antioxidant mechanisms involving enzymatic and non-enzymatic 
pathways are in place to prevent ROS accumulation. Notably, antioxidant molecules like 
vitamins A and E, glutathione, bilirubin and co-enzyme Q assist in quenching ROS in the 
body. Enzymes belonging to the family of superoxide dismutases (SODs) or catalyses can be 
site-specific and help catalyze the reaction of superoxides to the less harmful hydrogen 
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peroxides and oxygen. SODs contain different cationic metallic reactive centres and are 
located in the cytoplasm (SOD1), mitochondria (SOD2) and even in the extracellular matrix 
(SOD3). Catalyses are concentrated primarily in peroxisomes that are located in proximity to 
mitochondria and glutathione peroxidises rely on its reactive sulphur centre to reduce ROS.  
Perturbations to the balance of antioxidant and oxidants, resulting in accumulation of 
ROS/RNS causes oxidative stress, and have been documented to cause breakages in the DNA 
double helixes, mismatches in the complementary DNA base-pairings and also base 
transversions [152]. Many studies also show that the build-up of ROS promotes disease 
pathogenesis by acting as a precursor to fuel chronic inflammation and malignancy. 
Metabolically active organs like the brain and the liver are also highly susceptible to ROS 
accumulation. ROS elevation in the brain has been reported to increase risks of Alzheimer’s 
disease [153, 154] while chronic hepatitis and liver fibrosis have been attributed to the 
accumulation of ROS in the liver [155, 156]. ROS has been reported to cause mutations in 
critical cell cycle proteins like checkpoint kinases 1/2 (Chk1 and Chk2) and ataxia 
telangiectasia (ATM), as well as induce G2-M phase cell cycle arrest [157]. Others found that 
the increase in ROS [158, 159] in the hypoxic tumor environment stimulated the subsequent 
augmentation of TNF-α, COX-2 [160], NF-κB [161], STAT3 [162] and JNK/p38 MAPK 
[163] activity, which brought about further increase in IL-6, TNF-α and BCL-XL levels, 
hence promoting tumor cell survival, migration and metastasis.  
 
1.2.3 TAK1 Expression and Regulation in Chronic Inflammation and Cancer 
The transcription factors nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) are 
critical regulators of stress responses, immunity, inflammation and cancer. A large variety of 
cellular stimuli utilize these signaling pathways through a common upstream kinase 
transforming growth factor-β-activated kinase 1 (TAK1). TAK1 belongs to the family of 
mitogen-activated protein kinase kinase kinase (MAPKKK) class of threonine/serine kinases 
and is encoded for by the MAP3K7 gene on chromosome 6. TAK1 has been found to 
complex with both Tab1 and Tab2 proteins in the cytosol to facilitate its downstream 
signaling. The association with Tab1 is believed to activate the TAK1 kinase activity [164] 
while Tab2 assists in the binding with the TRAF6 complex [165]. TAK1 deficiency in mouse 
resulted in embryonically lethal phenotypes because of the inability to undergo important 
processes like angiogenesis and vascularization during development [166].  
TAK1 has been well characterized in recent literature in playing pivotal roles in development 
and innate inflammation and has been found to respond to a plethora of inflammatory 
stimulation. Bacterial LPS, inflammatory cytokines and TLRs have been reported to 
stimulate TAK1 activity [167-171]. Although non-canonical, it was also reported that TGFβ 
can stimulate TAK1 activity through Smad3 independent pathways [172]. TAK1 was also 
found to phosphorylate other downstream MAP kinases, culminating in the activation of 
transcription factors like p38 MAPK, NF-κB and AP-1 that regulates pro-inflammatory genes 
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[173-176]. Importantly, evidence have showed that TAK1 deficiency decreases cJun 
activation and promotes ROS production and inflammation in the skin [177]. Others 
demonstrate that TAK1 phosphorylates MAPKs [178] and increases TNF-α signaling [179, 
180], resulting in the increased production of COX-2 and ROS.  
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1.3 ANGIOPOIETINS AND ANGIOPOIETIN-LIKE PROTEINS  
There are 4 members that make up the angiopoietin family of proteins (Ang). While pro-
angiogenic Ang1 was found to bind its cognate receptor Tie1 and Tie2 to promote 
angiogenesis and downstream vessel remodelling [181], it was later reported that Ang2 
antagonises this effect by competitive binding to Tie2 [182]. Angiopoietins were first 
identified to be mediators of blood vessels formation during embryonic and postnatal 
development, and also for the assemblage of the vascular endothelial wall [183, 184].  
The Ang family of proteins share structural and sequence homology to the Angiopoietin-like 
family of proteins (ANGPTL) because both Ang and ANGPTL family of proteins are 
characterized by a coiled-coil N-terminal domain with a fibrinogen-like C-terminal domain 
[185-187]. ANGPTL represents a family of 8 proteins. But unlike their cousins, ANGPTL do 
not bind Tie proteins to mediate downstream responses. To date, ANGPTL remain as orphan 
ligands with little knowledge on their direct binding partners. Thus far, studies have observed 
that ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL5, ANGPTL7 are involved in hemapoietic 
stem cell maintenance and regulation while ANGPTL3, ANGPTL4, ANGPTL6 and 
ANGPTL8 have been reported to mediate glucose and lipid metabolism [188-190]. Recent 
studies have also detailed the multifaceted role of ANGPTL in inflammation and cancer 
progression and metastasis [191-193]. 
 
1.3.1 Angiopoietin-like 4 (ANGPTL4) 
ANGPTL4 is perhaps one of the most important members of the ANGPTLs because it 
mediates a broad variety of processes. Studies show that ANGPTL4 is involved in a wide 
assortment of pathways ranging from energy homeostasis, wound repair, inflammation and 
cancer [194-197]. Emerging evidence indicates that ANGPTL4 alters endothelial barrier 
integrity and is involved in cancer cell migration and metastasis [198]. Lately, the 
dysregulation of ANGPTL4 has also been attributed to complications associated with the 
metabolic syndrome. 
 
1.3.1.1 Expression and Regulation of ANGPTL4 
ANGPTL4 is a secretory adipokine previously known as fasting induced adipose factor 
(FIAF), hepatic fibrinogen/angiopoietin-related protein (HRARP) and peroxisome 
proliferator-activated receptor gamma angiopoietin-related protein (PGAR). The ANGPTL4 
protein is encoded for by the ANGPTL4 gene, a 11.09 kb gene located on human 
chromosome 19, and translated into a 406-amino acid long protein. On the other hand, the 
mouse ANGPTL4 gene is 6.6 kb on chromosome 17 encoding for a 410-amino acid 
ANGPTL4 protein. The molecular weight of full length ANGPTL4 (fANGPTL4) in both 
mice and humans remains contentious, ranging between 45 to 65 kDa due to post-
transcriptional modifications such as glycosylation (Figure 1.6).  
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Figure 1.6 Regulation and function of Angiopoietin-like 4 (ANGPTL4). Proprotein convertases like 
furin have been reported to recognize a conserved sequence –RRKR- of non-functional full length 
ANGPTL4 (fANGPTL4) to give an N-terminal coiled-coil fragment (nANGPTL4, 26 kDa) as well as a C-
terminal fibrinogen-like fragment (cANGPTL4, 35-47 kDa). Functional nANGPTL4 oligomerizes into 
dimmers or tetramers, and has been found to inhibit lipoprotein lipase (LPL), primarily controlling 
downstream fat metabolism and storage. On the other hand, functional cANGPTL4 exists as 
monomers. Recent findings direct the function of cANGPTL4 to play regulatory roles in inflammation, 
as well as tumor cell survival and proliferation. Modified and reprinted from Mol Cancer Res, 2012, 
10, 677-688, Tan MJ et al, Emerging Roles of Angiopoietin-like 4 in Human Cancer, with permission 
from AACR.  
 
Once secreted, fANGPTL4 is cleaved by proprotein convertases at the -RRXR- consensus 
region to give a 25 kDa N-terminus coiled-coil fragment (nANGPTL4) and a 25-35 kDa C-
terminus fibrinogen-like fragment (cANGPTL4). To date, the proteolytic cleavage 
mechanism of fANGPTL4 remains to be elucidated. In vitro studies have shown that 
proprotein convertases like furin and paired basic amino acid-cleaving enzyme 4 can cleave 
fANGPTL4 at its consensus site [199]. However, little is known if these proprotein 
convertases are indeed responsible for the in vivo processing of secreted fANGPTL4, or if the 
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expression of the different classes of proprotein convertases correlates to the presence of 
different ANGPTL4 fragments. Unlike cANGPTL4 which exists as a monomer, disulfide 
bond formation at the highly conserved 76 and 80 residues of the N-terminus coiled-coil 
domain allows fANGPTL4 to oligomerize and exist either as a tetramer or a dimer [200]. 
Likewise, the nANGPTL4 fragment also oligomerizes after cleavage and regulates lipid 
metabolism via its interaction with lipoprotein lipase.  
During hypoxia, the expression of hypoxia-inducing factor 1α (HIF-1α) is up-regulated, 
which mediated downstream ANGPTL4 expression [201, 202]. ANGPTL4 is also a direct 
target gene of the nuclear receptor PPAR (peroxisome proliferator-activated receptor) and 
functional PPAR response element (PPRE) resided in the intron 3 of the ANGPTL4 gene 
[203]. HIF-1α and PPAR were also found to synergistically up-regulate the expression of 
ANGPTL4 [204]. Other reports indicated that a variety of growth factors and stimuli like the 
toll-like receptors (TLRs), transforming growth factor beta (TGFβ), glucocorticoid receptor 
(GR), the metabolites from gut microbes and even the circadian rhythm signals 
ARNT2/SIM1 also regulate the expression of ANGPTL4 [188, 205-210]. 
fANGPTL4 is readily detected in hepatocytes, adipocytes and macrophages, as well as a 
lower level in other tissues such as the skin, kidneys and intestines [188] while cANGPTL4 
and nANGPTL4 fragments are detected in the liver [203, 211]. The nANGPTL4 associates 
with lipoproteins [212] and also inhibits the activity of lipoprotein lipases (LPL). This 
interaction is dependent on the oligomerization of nANGPTL4 fragments in order to 
effectively inhibit LPL and participate in lipid metabolism [213] (Figure 1.7). Hence, the 
function of nANGPTL4 hinges on its ability to form active three-dimensional structures 
which are functional. In contrast, the cANGPTL4 fragment exists as a monomer. cANGPTL4 
associates with specific extracellular matrix proteins, β1 and β5 integrin molecules [214]. In 
wound healing, cANGPTL4 facilitates keratinocyte migration through the FAK/Src/PAK-1 
cascade [215]. The cANGPTL4 also suppresses angiogenesis through the inhibition of the 
Raf/MEK/ERK pathway [216]. Furthermore, cANGPTL4 also increases the O2
-
:H2O2 ratio, 
promoting tumor cell survival and proliferation [197]. Put together, these evidences suggest 
that the expression of specific ANGPTL4 fragments is tissue/organ dependent, and that the 
various ANGPTL4 fragments play distinct cellular functions. 
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Figure 1.7 The paracrine effects of Angiopoietin-like 4 (ANGPTL4) in lipid metabolism. ANGPTL4 is 
chiefly expressed in the liver, white adipose tissue (WAT), skeletal muscle but is recently reported to 
be also expressed in macrophages, heart as well as enteroendocrine cells in the intestine. The 
function of ANGPTL4 in lipid metabolism is tissue specific, and is primarily under the regulation of 
peroxisome proliferator-activated receptors (PPARs) and glucocorticoid receptors (GRs). In WAT, 
increased ANGPTL4 stimulation inhibits lipoprotein lipases and increases lipolysis of accumulated 
triglycerides. Because the liver does not produce LPL, ANGPTL4 is secreted into the circulation and 
targeting peripheral LPL activity. In the muscle, heart and in macrophages and intestinal 
enteroendocrine cells, positive stimulation by fatty acids increases ANGPTL4 levels, bringing about an 
inhibition of local LPL activity. Reprinted from Trends in Endocrinology & Metabolism, 25/3, Dijk W et 
al, Regulation of lipoprotein lipase by Angptl4, Pages No. 146–155, Copyright 2014, with permission 
from Elsevier.  
 
Up till now, there is no known protein crystal structure of fANGPTL4, cANGPTL4 or 
nANGPTL4. Current knowledge of the different roles of ANGPTL4 fragments were 
elucidated via a combination of biochemical analysis and ANGPTL4-knockout animal 
model. ANGPTL4 has been implicated to play a role in tumorigenesis, however its effect 
remained controversial. Although the precise reason for the controversy is unclear, it is 
conceivable that different ANGPTL4 fragments may be involved, as these fragments have 
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been reported to stimulate different signaling cascades Thus, more effort is required to 
elucidate the structures and functions of the different ANGPTL4 fragments. 
 
1.3.1.2 ANGPTL4 and Metabolism 
The oligomerized nANGPTL4 inhibits LPL and regulates lipid metabolism (Figure 1.8). 
LPLs are found at the luminal surface of capillary endothelial cells and are regulated by 
hormones like insulin, glucagon and adrenaline. LPL homodimers hydrolyses plasma 
triglycerides found in VLDL into intermediate-density lipoproteins (IDL) and eventually into 
free fatty acids (FFA), allowing the subsequent uptake of fatty acids into the liver, adipocytes 
and macrophages for storage purposes. ANGPTL4 mediates the rate of plasma triglyceride 
clearance. fANGPTL4 and nANGPTL4 oligomers cause the dissociation and subsequent 
inactivation of LPL dimers, resulting in the inhibition of triglyceride hydrolysis. Furthermore, 
it was observed that ANGPTL4 further exacerbates the inhibition of triglyceride hydrolysis 
by targeting LPLs for proteolysis by proprotein convertases [199]. However, studies also 
showed that increasing circulating ANGPTL4 further increases plasma FFA levels through 
increasing cholesterol and fatty acid synthesis [211, 217], suggesting a negative feedback 
mechanism on plasma LPL inhibition. The over-expression of ANGPTL4 was also 
demonstrated to increase levels of nonesterified fatty acids (NEFA) in adipocytes [212] and 
cause hypertriglyceridemia in mice [212, 218].  
Apart from lipid metabolism, ANGPTL4 was recently found to be involved in glucose 
metabolism. ANGPTL4 has been shown to reverse glucose insensitivity in diabetic mice. 
ANGPTL4 lowers hyperglycemia primarily through augmenting insulin-dependent inhibition 
of gluconeogenesis and impeding glucose synthesis in the liver [219]. In adipocytes, insulin 
down-regulates ANGPTL4 levels through the PI3K/FOXO1 signalling cascade [220].  
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Figure 1.8 Inflammatory pathways implicated in insulin and FFA stimulation. Insulin binds cell 
surface insulin receptors to increase glucose uptake into cells predominantly through the 
phosphorylation of IRS, leading to the activation of the PI3K/AKT and Ras/MAPK signaling cascades 
to support growth and development. The abundance of FFA in the system hyperactivates TLRs and 
other chemokine receptors, causing an increase in phosphorylation of downstream inflammatory 
mediators like IKKB and JNK. Signaling through the NFκB and AP1 (Jun/Fos) pathway increases, 
leading to an increase but impaired expression of inflammatory components. The activation of IKKB 
and JNK serine kinases also inhibits the signaling ability of IRS, which further impairs conventional 
insulin signaling. In turn, other inflammatory signals like NO and SOCS also impairs the activity of IRS 
signaling, resulting in an overall increase in the production of inflammatory mediators and a 
decrease in normal glucose uptake and metabolism. Reprinted from FEBS Letters, 582/1, De Luca C 
et al, Inflammation and Insulin Resistance, Pages No. 97–105, Copyright 2008, with permission from 
Elsevier.  
 
1.3.1.3 ANGPTL4 and Inflammation 
The dysregulation of ANGPTL4 impacts lipid and glucose metabolism, leading to obesity-
induced inflammation and the unwanted accumulation of fat and energy storage [221, 222]. 
The increase in FFA and SFA was found to positively regulate pro-inflammatory cytokine 
production and insulin resistance, the latter directly involved in mediating cellular glucose 
uptake [223, 224]. FFA and SFA also hyperactivates Toll-like receptor 4 (TLR4), resulting in 
the activation of an assortment of immune responses. In turn, this triggers the synthesis and 
secretion of increased levels of pro-inflammatory cytokines like TNF-α and IL-6 [225]. 
Augmented pro-inflammatory signals further activate downstream S6K/IRS/PI3K/AKT 
signalling cascade in a positive feedback manner, causing the eventual insulin resistance and 
development of type II diabetes.  
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Numerous studies have implicated a role for ANGPTL4 in inflammation, where ANGPTL4 
plays either anti- or pro-inflammatory roles in a context- or tissue-dependent manner. 
ANGPTL4 prevents foam cell formation by inhibiting fatty acid uptake into mesenteric 
lymph node macrophages, thus protecting against severe pro-inflammatory effects of 
saturated fatty acids [226]. ANGPTL4 also protects against atherosclerosis development 
[227] and acts as an angiogenic mediator in arthritis [227, 228]. ANGPTL4 was observed to 
exacerbate influenza and inflammation through independent IL-6-STAT3 and SIRT1-NFkB 
mediated pathways in the lungs [196, 229]. Interestingly, serum ANGPTL4 was correlated to 
C reactive protein (CRP) levels in type II diabetic patients, suggesting that ANGPTL4 might 
be involved in the inflammatory progression during the metabolic syndrome [230]. In the 
context of infection-associated inflammation, bacterial lipopolysaccharide (LPS) was found 
to be able to up-regulate ANGPTL4 expression in the mouse serum within 8 hours upon LPS 
stimulation and was subsequently labelled as an acute phase protein [231]. Furthermore, it 
was also shown that stimulating 3T3-L1 adipocytes with inflammatory chemokines like IL-
1β, TNF-α, IFN-γ increases ANGPTL4 expression. Another independent group has also 
shown that the acute phase protein α1-antitrypsin (A1AT) increases ANGPTL4 expression 
through ERK1/2 signaling cascade [232]. Albeit the numerous reports of the role of 
ANGPTL4 in inflammation, the pathways by which ANGPTL4 modulates inflammation are 
largely unknown and remains unclear.  
 
1.3.1.4 ANGPTL4 and Cancer 
We consider the immune system as our friend; it protects us by fighting infections while 
keeping us healthy. But there is a darker side to the immune system. Often, when it comes to 
cancer, we find that the immune system can turn traitor and actually promote cancer 
development. The presence of leukocytes in tumors has been noted for many decades and 
provides the first clue that inflammation is linked to cancer. Yet it is only within the last few 
years that we have obtained clear evidence that inflammation plays a critical role in cancer 
development, and we are just beginning to understand the molecular mechanisms of how this 
happens. Indeed, chronic infections, obesity, smoking, alcohol consumption, environmental 
pollutants and high fat diets are now recognized as major risk factors for most common types 
of cancer; and, importantly, all these risk factors are linked to cancer through inflammation. 
In an inflammatory and oxidative milieu, cells begin to accumulate damages to their DNA 
that facilitates the accumulation of pro-oncogenic mutations. Furthermore, the incessant 
secretion of ROS, MMPS, cytokines, chemokines and other soluble pro-inflammatory factors 
like CSF-1 and IL-6 by tumor-associated macrophages (TAMs) amongst other inflammatory 
infiltrates, potentiates angiogenesis and tumor progression [233]. TAMs also secrete TGFβ, 
TNF-α and IL-10 [234, 235], and attenuating cytotoxic T cell activation [236]. Coupled onto 
sustained cell proliferation, reduced DNA repair and the subversion of apoptosis, cells in the 
chronic inflammatory environment develop neoplastic phenotypes and progress into cancer 
[237, 238]. 
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A role for ANGPTL4 in regulating inflammation has been implicated (see above, chapter 
1.3.1.3). Conceivably, ANGPTL4 has a well-described role in carcinogenesis. ANGPTL4 is 
both a pro-angiogenic and anti-apoptotic factor that promotes endothelial vascularisation 
[209, 228, 239, 240]. Recently, we found that ANGPTL4 facilitates cell migration [215] and 
also regulates intracellular oxidative O2
-
:H2O2 ratios in tumors [197], In addition, ANGPTL4 
has also been implicated in cancer progression and metastasis. Independent groups have also 
reported that ANGPTL4 levels were increased in gastric cancer cells [241] and renal 
epithelial tumor cells [242, 243]. Nakayama et al and Shibata et al proposed that ANGPTL4 
play significant roles in both venous and lymphovascular invasion [241, 244], suggesting that 
ANGPTL4 affects tumor migration and metastasis. Others identified ANGPTL4 as a marker 
of breast-lung metastasis [207] and oral squamous cell carcinoma [245]. These findings 
suggest that ANGPTL4 is a potential regulator in cancer progression and tumor 
vascularisation. Even though ANGPTL4 has been identified to play vital roles in regulating 
both inflammation and tumorigenesis, the exact roles by which ANGPTL4 regulates cancer 
through inflammatory pathways remain to be elucidated. Therefore, it is of utmost 
importance to understand the relationship between the ANGPTL4-dependent, inflammation-
tumorigenesis signalling axis.  
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2 AIMS 
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We aim to explore various ANGPTL4-dependent intermediates that regulate the 
inflammatory landscape. Using independent models, we further delineate the respective 
signaling cascades that primarily govern both the acute and chronic phases of inflammation in 
the inflammation-cancer signaling axis.  
 
Figure 2.1 A graphical summary of ANGPTL4-dependent signaling cascades during acute and 
chronic inflammation which promotes epithelial-to-mesenchymal transition.  
 
In PART I of this thesis, we demonstrate that the importance of ANGPTL4 in regulating the 
acute colonic inflammatory environment. 
I. An anti-inflammatory role for colonic ANGPTL4 in dextran sulfate sodium salt 
(DSS)-induced colitis and dietary stearic acid (SA) intake. 
II. The role of the commensal gastrointestinal microbiota in inflammation.  
III. The intrinsic role of colonic ANGPTL4 in regulating leukocyte infiltration during 
DSS-induced inflammation, and thus, the colonic inflammatory landscape.  
IV. The underlying mechansims involving the regulation of Tristetraprolin (TTP) through 
CREB and NF-κB transcription factors.  
In PARTS II and III of this thesis, we aim to understand the role of TAK1 and ANGPTL4 
in regulating ROS production during the chronic inflammatory state in the tumor 
microenvironment.  
V. The role of TAK1 and ANGPTL4 in mediating the pro-inflammatory ROS landscape 
in the early, pre-tumor microenvironment.  
VI. To understand the role of ROS in promoting field cancerization. 
VII. To delineate possible signalling downstream of ANGPTL4 during chronic 
inflammation that promotes tumor cell migration and the epithelial-mesenchymal 
transition (EMT) process.   
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3 METHODOLOGY 
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3.1 METHODOLOGICAL HIGHLIGHTS 
Detailed experimental methodologies can be obtained in the individual papers and 
manuscripts. Therefore, this section will describe methodological highlights utilized in this 
thesis.  
3.1.1 Bone Marrow Tranplantation 
 
Figure 3.1 Experimental Timeline for the Bone Marrow Transplant. 
 
To exclude the cell-autonomous (intrinsic) effects of ANGPTL4 originating from non-colonic 
epithelial cells, we further performed a bone marrow transplant using the bone marrow from 
donor ANGPTL4
-/-
 or ANGPTL4
+/+
 mice to recipient ANGPTL4
+/+
 mice (Figure. 3.1). 
Recipient mice were kept on acidified water (pH 3.0) over the course of the entire 
experiment. BMT (ANGPTL4
-/-
) and BMT (ANGPTL4
+/+
) chimeras were medicated with 
trimethoprim (8 mg/kg) and sulfamethoxazole (40 mg/kg) in oral suspension (Allpets Asia, 
Singapore) for one week before and after lethal γ-irradiation (9.5 Gy), using the Biobeam 
8000 (Gamma-Service Medical GmbH).   
  
Figure 3.2 Bone Marrow Transplant Procedures. 
 
Donor bone marrow cells from the humerus, tibia and femur of donor mice were isolated in 
serum-free DMEM. Cells were first washed with PBS followed by red blood cells lysis 
[0.89% NH4Cl (w/v), 0.1 mM EDTA, pH 7.2]. Cells were filtered through a 30 µm nylon cell 
48 
strainer before depleting mature CD4
+
 and CD8
+
 donor immune cell populations 
(QuadroMACS kit with anti-CD4- and anti-CD8a-conjugated microbeads, #130-049-201, 
#130-049-401 and #130-091-051; from Miltenyi Biotec; in accordance to manufacturer’s 
recommendations; degassed, ice cold PBS containing 0.5% BSA, 2 mM EDTA at pH 7.2). 
Cells were resuspended in serum-free DMEM and approximately 10
7
 bone marrow cells (in 
100 µL total injected volume) were introduced into WT IR recipient mice via retro-orbital 
injection (Figure 3.2). BMT (ANGPTL4
-/-
) and BMT (ANGPTL4
+/+
) chimeras were allowed 
to recover for 4 weeks before the subsequent 8-day 2% DSS treatment.  
Hematopoietic reconstitution was evaluated using genotype PCR. At experimental endpoint, 
cell counts were performed for the whole femur and spleen tissues using the ADAM-MC cell 
counter (NanoEntek, USA). Splenic and colonic cells were analyzed for F4/80 and CD11b 
expression using FACS (BD LSRFortessa X-20) to determine the extent of immune cell 
infiltration.  
 
3.1.2 16S Metagenomics Sequencing 
Age-matched, post-weaned ANGPTL4
-/-
 and ANGPTL4
+/+
 males were co-housed for the 
entire experiment. Fresh fecal samples were collected from both ANGPTL4
-/-
 and 
ANGPTL4
+/+
 littermates before and after 8-day 5% DSS treatment, and stored at -80 
o
C. 
Bacterial genomic DNA was isolated using the FASTDNA spin kit for feces in accordance to 
manufacturer’s recommendations (MP Biomedicals, USA; #116570200). 16S metagenomics 
sequencing was performed by SeqMatic, USA, using primers targeting the 16S V4 region by 
means of the high throughput NGS Illumina MiSeq platform.  
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3.1.3 Transwell Migration Assay 
THP1 monocytes were initially differentiated into macrophages by incubating cells in 
DMEM supplemented with 10% FBS and 100 ng/mL TPA for 48 h. Cells are left to recover 
for 24 h before seeding onto transwell inserts. Concurrently, respective siRNA knockdowns 
were performed on iCECs (iCECCtrl, iCECANGPTL4 and iCECTTP) that were pre-seeded onto 
wells. Cells on both the inserts and wells are kept apart until the start of the transwell 
migration experiment as shown in Figure 3.3.  
 
Figure 3.3 A graphical illustration of the transwell migration assay set up. 
 
Inserts containing differentiated THPI-derived monocytes were then introduced to the 
respective transfected iCECs and exposed to various pro- or anti-inflammatory stimuli for 10 
h. Subsequently, inserts were then removed and rinsed twice with PBS and fixed in 1% 
glutaraldehyde for 10 min. Inserts were rinsed again and stained with SYTO 60 (Thermo 
Fisher, USA) for 30 min. Consequently, cotton buds were used to scrape away all non-
migrated THP1 cells trapped within the upper chamber of each insert and rinsed for the last 
time in PBS. Relative fluorescence was quantified using the CLx scanner and Image Studio 
V2.1 (LI-COR Biosciences, USA).  
 
3.1.4 Statistical Analysis 
Statistical analyses were performed using 2-tailed Mann Whitney U-test using Graphpad 
Prism 5 and Microsoft Excel software. P values are expressed as means ± standard error; and 
p < 0.05 represent statistically significant differences, where * denotes p < 0.05; ** p < 0.01 
and *** p < 0.001.  
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4.1 ANGIOPOIETIN-LIKE 4 IN ACUTE INFLAMMATION  
Recent studies report that Angiopoietin-like 4 (ANGPTL4) plays a multi-faceted role in the 
regulation of host inflammatory response. ANGPTL4 has been observed to play angiogenic 
roles in mediating arthritis [227, 228] and atherosclerosis development [227]. ANGPTL4 was 
found to exhibit anti-inflammatory functions in preventing macrophages from absorbing fatty 
acids, hence preventing foam cell formation [226]. However, others attribute ANGPTL4 to 
exacerbating inflammation. Serum C-reactive protein (CRP) levels have been correlated to 
ANGPTL4 expression in patients with type II diabetes [230]. LPS was detailed to positively 
up-regulate ANGPTL4 expression [231]. To date, ANGPTL4 has been shown to exert both 
anti- and pro- inflammatory responses through a wide array of stimuli. However, little is 
known about how ANGPTL4 regulates inflammation.  
In Part I of this thesis, we sought to outline possible mechanisms that could explain the anti-
inflammatory role of ANGPTL4 (Figure 4.1). Using both dietary C18 saturated fatty acid 
(stearic acid; SA) and dextran sodium salt (DSS) as separate models to induce acute 
inflammation in mice, we show that mice exhibited an exacerbated inflammatory response in 
the absence of ANGPTL4. Confirming the current paradigm, 16S metagenomics sequencing 
showed little differences in the microbiota communities between the genotypes at steady state 
but show divergence during DSS-induced inflammation [246-248]. Both microarray analysis 
and bone marrow transplantation experiments further affirm the importance of epithelial-
derived ANGPTL4 in regulating the local inflammatory landscape. Subsequently, we 
demonstrated an increased stability in a subset of chemokines that were previously found to 
be regulated by an mRNA destabilizing protein, TTP. To reconfirm our in vivo findings, we 
subjected SV40-immortalized human colonic epithelial cells (iCECs) to pro- and anti-
inflammatory treatments. We observe that ANGPTL4 and TTP expression decreases with 
pro-inflammatory treatments and increases with anti-inflammatory stimulation. In summary 
Paper I demonstrated that ANGPTL4 is able to regulate the inflammatory landscape through 
TTP-dependent and TTP–independent pathways.  
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Figure 4.1 A graphical summary of the TTP-dependent ANGPTL4 signaling axis. cANGPTL4 mediates 
colon epithelial cell homeostasis by regulating TTP expression. At basal state, cANGPTL4 stimulation 
maintains TTP expression through the phosphorylation of transcription factors CREB and NF-κB. TTP 
binds at the AU-rich regions of the chemokine 3’ UTR, causing the degradation of target chemokine 
mRNA transcripts. During inflammation, positive p38MAPK-MK2 signaling causes the 
phosphorylation of TTP, allowing the 14-3-3 complex to sequester and inactivate TTP. Chemokine 
transcription ensues, bringing about increased amounts of chemotactic signals to aid the infiltration 
of immune cells and to remove the source of inflammation.  
 
In a similar genome-wide study aimed at identifying the differences in the gene expression 
between UC and Crohn’s disease (CD), Wu et al found that even though UC and CD resulted 
to similar clinical IBD characteristics, each disease exhibited a unique and non-overlapping 
pattern of genomic expression (GSE6731) [249]. Using their study cohort of CD, we 
conducted a comparative microarray gene expression analysis of CD patients against our 
murine ANGPTL4
+/+
 and ANGPTL4
-/-
 colon samples (Figure 4.2).  
Unlike UC, the gene expression and hierarchical clustering profile was very different between 
human CD and murine samples (Figure 4.2a). Gene ontology analysis demonstrates that top 
molecular and cellular functions include cellular movement, cellular growth and proliferation, 
as well as cellular function and maintenance (Figure 4.2b). Further inquisition identified a 
region of differentially expressed inflammatory genes (black box demarcated in Figure 4.2a), 
but primary canonical pathways that were affected were not confined to the gastrointestinal 
tract (Figure 4.2c). One conceivable explanation to this difference is the varying aetiology 
and manifestation of UC and CD even though they belonged to the category of IBD. UC is 
limited to the colon, while CD has been reported to mostly affect the ileum and the colon, as 
well as other regions of the gastrointestinal tract. Recent correlation studies also suggest that 
CD might also be hereditary, and that genetic factors (mutations in genes like NOD2, IRGM, 
ATG16L1) are also believed to be contributing to the development of CD [250, 251].   
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Figure 4.2 Comparative microarray gene expression analysis between colonic samples from DSS-
challenged mice and human Crohn’s disease. (a) Microarray heat map showing changes in gene 
expression between murine ANGPTL4+/+ and ANGPTL4-/- mice treated with DSS, and inflamed and 
non-inflamed Crohn’s disease (CD) biopsies (GSE6731). (b) The IPA database ranks genes responsible 
for regulating cellular movement, cellular growth and proliferation, as well as cellular maintenance 
amongst the most significantly varied between murine and human samples. (c) Inflammatory genes 
that were found to be differentially expressed (as demarcated by the black box in figure 4.2a), were 
primarily responsible for the regulation of inflammatory processes not limited to the gastrointestinal 
tract.  
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4.2 TAK1 DEFICIENCY PROMOTES PRO-INFLAMMATORY ROS LANDSCAPE 
FOR FIELD CANCERIZATION  
As a classical theory that connects inflammation and cancer, the sustained state of chronic 
inflammation and irritation has frequently been correlated to drive spontaneous tumor 
development [238]. Epithelial cells in the chronic inflammatory environment are exposed to 
ROS and are at risk of accumulating unwanted DNA mutations that could further impede 
tumor suppressor mechanisms in place to prevent tumor formation. Under typical 
circumstances, the accumulation of ROS-dependent DNA damage or genomic instability 
would result in senescence or apoptosis via the p53 pathway [252]. However, most tumor 
cells are incapable of responding to the accumulation of oxidative stress levels because of 
defective anti-oxidant signaling pathways [253], which further leads to tumor malignancy.  
In Part II of this thesis, we capitalized on a variety of tumorigenic cultures like A5RT3, 
MKN78, HSC-5 and the non-metastatic Hacat to show that epithelial to mesenchymal 
transition (EMT) is favored with TGFβ stimulation through the canonical Smad3 signaling 
axis. Interestingly, Paper II showed that the depletion of TAK1, a non-canonical TGFβ 
signaling partner, further promotes cytoskeleton remodeling and EMT. Similar to other 
groups, we validate a sustained production of ROS in TAK1-ablated cells [254, 255]. We 
further demonstrate an increase in Rac1-Nox1 activation and a corresponding decrease in 
RhoA activity in TAK1-depleted cells, which further elevates ROS levels in the 
microenvironment. An increase in Rac1-Integrin β1 interaction and an augmented expression 
of mesenchymal markers like vimentin, N-cadherin, fibronectin and Snai1/2 also hint at the 
initiation of cell migration. An increase in cell traction force was also recorded for cells 
depleted of TAK1. Put together, our data suggests a regulatory role of endogenousTAK1 in 
Rac-RhoA activation in limiting ROS production, as well as cytoskeleton remodeling and cell 
migration (Figure 4.4).  
Follow-up investigations in a related publication reveal that H2O2 levels are positively 
correlated to increasing tumor aggressiveness and the intensity of diffused H2O2 throughout 
the tumor epithelial and stromal regions is amplified with increased malignancy [256]. Since 
the early days of cancer treatments, surgeons and oncologists alike have reported a rising 
trend of patients developing recurrent second primary malignancies even after the successful 
removal of the index tumors. As such, Slaughter et al first coined the term ‘field 
cancerization’ in 1953 when they first demonstrated histological changes in the epithelium 
that resided beyond the tumor boundary [257].  The heterogeneous population of cancer-
associated fibroblasts (CAFs) which reside in the adjacent stroma is also believed to sustain 
tumor proliferation and metastasis. However, due to the complexity of defining the region 
beyond the tumor that possesses malignant transformations, research contributions towards 
field cancerization remains in its infancy. To date, it was noted that almost 30% of all cancer-
related deaths are attributed to second primary malignancies and this remains an important 
finding in cancer treatment regimens and research.  
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Figure 4.4 A graphical summary of the TAK1-dependent signaling cascade which promotes 
epithelial-to-mesenchymal transition. TAK1 activity in benign cells protects against the TGFβ-Smad3 
stimulation in the tumor environment. As cells lose TAK1 expression, cells respond by increasing 
Rac1-Integrin β1/3 interactions, promoting increased activity of Rac1-Nox1 complex formation. This 
association increases the production of reactive oxygen species (ROS), which further fuels the up-
regulation of inflammatory cytokines, resulting in the formation of a chronic inflammatory landscape 
in the tumor microenvironment. Elevated ROS levels also suppress the expression of epithelial 
marker E-cadherin but raise the levels of mesenchymal markers like vimentin and N-cadherin. In this 
respect, undergo cytoskeleton remodeling, allowing for the increase the number of focal adhesions 
and stress fibers to facilitate migration.   
 
Experimental findings reveal that not only does H2O2 increase the invasiveness of epithelial 
cells, H2O2 also disrupts cellular homeostasis by oxidizing key signaling intermediates like 
PTEN, Src, JNK and EGFR. We show that fibroblasts incubated with the conditioned media 
of CAFs experience a similar oxidative stress with those treated with exogenous H2O2. Along 
with the reduction of Smad3 and TAK1 expression, our data show that H2O2–treated 
fibroblasts quickly become desensitized to TGFβ stimulation. Similar to our earlier findings, 
we demonstrate that the reduction in Smad3 and TAK1 signaling further increases ROS 
production and p65-NF-κB activity in fibroblasts, elevating the overall oxidative stress while 
promoting a pro- inflammatory microenvironment. These combined conditions not only 
cause cells to develop resistance to TGFβ signaling, it also primes the conversion of 
fibroblasts to become CAFs. Interestingly, we found that CAFs express low levels of Gpx1, 
rendering them incapable of detoxifying ROS and hence, allowing for the accumulation of 
oxidative stress. In all, our data is in agreement that ROS-induced chronic inflammation is 
sufficient to give a pro-inflammatory and pro-tumor microenvironment which promotes field 
cancerization in the epithelium.  
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4.3 ANGPTL4 PROMOTES TUMOR CELL MIGRATION AND EMT  
In complex diseases like cancer, both the host immune system and the tumor (tumor cells and 
cells that make up the tumor microenvironment) play crucial roles in maintaining the 
dynamics that keep the cancer viable.  
Huang et al show that tumor cells express high levels of ANGPTL4 and that cANGPTL4 
interacts with junction proteins like claudin-5, VE-cadherin and integrin α5β1 to disrupt 
endothelial continuity and vascular integrity [198]. Kubo et al also reported that cancer cells 
exposed to hypoxic environments increased ANGPTL4 expression [258] while Tanaka et al 
found that ANGPTL4 increases the metastatic potential of tumorigenic cells [245]. Zhu et al 
demonstrated that ANGPTL4 levels correlated to increase ERK-AKT signaling in cancer, as 
well as increased E-cadherin and decreased vimentin expression [259], a feature that is 
characteristic of the EMT process.  
To understand the medical relevance of ANGPTL4, we first characterized the expression of 
cANGPTL4 in human tumor biopsies. We observed that cANGPTL4 is elevated with 
increasing stages of cancer in a stage-dependent manner (Figure 4.5a). In a submitted 
manuscript (Paper III), we also demonstrated that ANGPTL4 drives the EMT process by 
elevating cellular energy flux through 14-3-3γ-dependent signaling cascades.  We also found 
that ANGPTL4 phospho-activates AKT and AMPK in cancer cells during EMT and might be 
a possible modulator of cellular bioenergetics. Using polarized gastric carcinomas MKN74 
cells, we show that the induction of EMT accompanied by an increase in Glut 1 expression 
occurs within 48 hours post hypoxia exposure. Interestingly, this same hypoxia exposure 
delayed EMT in cells with impaired ANGPTL4 signaling (treated with neutralizing 
cANGPTL4 antibody; α-cANGPTL4). However, stimulation with recombinant cANGPTL4 
in normoxic conditions caused cells to lose their epithelial morphology and E-cadherin 
expression within 48 hours and was sufficient to drive cells into EMT (Figure 4.5b-c).  
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Figure 4.5 ANGPTL4 promotes cytoskeletal remodeling during epithelial to mesenchymal transition 
(EMT) and alters cancer cell bioenergetics. (a-b, d) Representative immunoblot analysis of (a) 
cANGPTL4 and (d) 14-3-3γ in human samples (purchased from Proteogenex, USA), of breast, 
colorectal, gastric and head and neck cancer samples with varying tumor stages and (b) Glut 1 in α-
cANGPTL4- and rh-cANGPTL4-treated MKN74 cells. (c) Immunofluorescence staining of the epithelial 
marker E-cadherin (in green) and phalloidin for the actin cytoskeleton (in red) in MKN74 gastric 
carcinoma cells, counterstained with DAPI (in blue). MKN74 cells were treated with rh-cANGPTL4 in 
normoxia (right panel), in hypoxia (middle panel) and in hypoxia with human cANGPTL4 antibody (α-
cANGPTL4; left panel) for 48 hours. A sharp decrease in E-cadherin expression and a remodeling of 
the actin cytoskeleton was observed at 48 hours with both rh-cANGPTL4 and hypoxia treatment. On 
the other hand, treatment with α-cANGPTL4 antibody rescued this loss and promoted EMT 
induction, suggesting that ANGPTL4 plays crucial roles in cytoskeletal remodeling during EMT. (e) 
Representative immunoblot analysis showing CREB/pCREB, cFOS/pcFOS and STAT3/pSTAT3 
expression in rh-cANGPTL4- and hypoxia-stimulated MKN74. Immunoblot analysis showing the 
expression of indicated proteins after co-immunoprecipitation of (f) TSC2, (g) 14-3-3γ or Snai1 during 
hypoxia-induced EMT in MKN74Ctrl and MKN74ANGPTL4 cells.  
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14-3-3 belongs to a family of highly conserved adaptor proteins and has been previously 
reported in regulating cell cycle proteins Chk1 [260], ATM and CDC25 [261], and also acute 
phase TTP during inflammation (Paper 1). In addition, we previously found that ANGPTL4 
augmented 14-3-3 expression during wound healing [195, 215], suggesting that ANGPTL4 
could modulate 14-3-3 during EMT. In addition to EMT-induced MKN74, we found that 
tumors at higher stages express elevated levels of 14-3-3γ but not other 14-3-3 isotypes 
(Figure 4.5d). Using a combination of the unbiased kinase inhibitor arrays and in silico 
analysis using the IPA software, we report that ANGPTL4 regulates 14-3-3γ transcription 
through transcription factors like CREB, cFOS and STAT3 (Figure 4.5e). The ANnotation 
and Integrated Analysis of the 14-3-3 interactome (ANIA) database also identified TSC2 and 
Snai1 as likely interaction partners of the 14-3-3 complex. To strengthen our findings, 
proximity ligation assays and co-immunoprecipitation experiments reveal an increase in the 
formation of 14-3-3γ:TSC2 and 14-3-3γ:Snai1complexes during EMT (Figure 4.5f-g). 
Similarly, we also observed significantly more 14-3-3γ:TSC2 and 14-3-3γ:Snai1complexes in 
aggressive human tumors biopsies as compared to their benign controls. We also demonstrate 
that 14-3-3γ stabilizes Snai1 binding to the E-cadherin promoter region during EMT, 
allowing for the transcription of the E-cadherin. Put together, our findings show that 
ANGPTL4 exert control over the EMT process by stabilizing key EMT proteins and meeting 
the increased cellular energy demands through AKT-dependent pathways. More importantly, 
our data underscores the significance of the ANGPTL4: 14-3-3γ signaling axis during EMT.  
Interestingly, Wang et al, Griseri et al and Young et al recently discussed about the 
importance of proteins like TTP and HuR that can regulate cytokine stability play important 
roles in inflammation-related cancers and also in cancer progression [262-264]. In this 
respect, the dysregulation in cytokine stability after the initial inflammatory phase allows for 
a persistent feedback loop of increased inflammatory signals (chronic inflammation) and 
generation of ROS around the developing tumor. Since there is a need for increased nutrient 
supply to support the growing tumor, genes that promote angiogenesis should also be highly 
expressed in the vicinity.  
To date, independent groups have brought forth convincing evidence to suggest that various 
cancers over-express immune checkpoint proteins as a method to evade immuno-surveillance 
[265]. Evolutionarily, the binding of PD-1 from B and T cells to its ligands PD-L1/2 
negatively regulates T cell activation, muting out immune responses to prevent protracted 
immune reactions and tissue injury. It was found that immune cells in the pro-inflammatory 
tumor microenvironment do not mount any anti-cancer response because of the increased 
PD-1/PD-L1 signaling, further lowering CD8
+
 T cell survival, proliferation and cytokine 
production [266, 267].  
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The advancement of Science and Research is both rapid and brisk. In a short span of time, 
seemingly new findings can pave the way to become novel applications aimed at increasing 
the efficiency of diagnostics. Hence, the need to keep abreast of new findings is crucial to 
pilot new experiments in directions that pioneer novel work. In this thesis, we explored 
possible regulatory pathways of ANGPTL4 in both acute and chronic inflammation, and also 
examined its role in promoting EMT and tumor metastasis.  
 
Figure 5.1 A graphical illustration showing ANGPTL4-dependent regulatory pathways during both 
acute and chronic inflammation. The induction of ANGPTL4 expression during acute inflammation 
initiates immune cell infiltration to the site of injury. Subsequently, ANGPTL4 stimulates TTP 
transcription, a RNA-binding intermediate which destabilizes cytokines. This quenches the local pro-
inflammatory landscape and returns the tissue to its non-inflamed state. During chronic 
inflammation, a tightly regulated shift in ANGPTL4 and TAK1/Smad3 signaling disrupts cellular 
homeostasis. Cells desensitize towards the steady state of inflammation and accumulate increasing 
amounts of reactive oxygen species. The increase in expression of mesenchymal:epithelial markers 
promotes cytoskeleton remodeling and causes cells to adopt a more mesenchymal phenotype. 
Augmented 14-3-3γ also inhibits TSC2, accommodating for the increase in cellular energy demands 
during EMT.  
 
We began by exploring the value of ANGPTL4 in regulating the immune landscape in both 
acute and chronic inflammatory states, leading up to cancer formation, EMT and metastasis 
(Figure 5.1). For the reason that functional ANGPTL4 exists in two forms with non-
overlapping roles (dimeric or tetrameric nANGPTL4 is primarily involved in energy 
metabolism while monomeric cANGPTL4 has been reported to mediate angiogenesis and 
inflammation), ANGPTL4 has been implicated to be an ideal environmental sensor. As such, 
the dysregulation of ANGPTL4 has been described in literature to influence the outcome of a 
variety of disease models varying from cancer metastasis, atherosclerosis, metabolic 
syndrome and acute inflammation in association to type II diabetes.  
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Aberrant energy metabolism leading up to the accumulation of excess fat in the body through 
nutritional and hormonal imbalance have also been under scrutiny as a cause for the rising 
global obesity trends. Recent findings suggest apart from conferring an immunological 
advantage, the gastrointestinal microbial community might be responsible to modulate host 
energy metabolism and disease susceptibility. Metabolomics has also spearheaded efforts in 
identifying the plethora of microbial metabolites and their effects on diseases and health 
[268]. In addition, nANGPTL4 mediates both glucose and lipid metabolism, suggesting that 
signaling crosstalk between the host and its commensal microbial community through 
ANGPTL4 remains to be investigated.  
Similar to the dysregulation of the inflammatory landscape during acute colonic 
inflammation, dietary fat like stearic acid could pose eminent health issues not limiting to 
inflammatory responses. Generally, common fat found in diet can be classified into saturated, 
unsaturated and trans fat categories. Using correlation studies, Corwin et al reported that 
saturated fat intake was inversely associated with bone mineral density [269] while Martínez-
Ramírez et al demonstrated that increased polyunstaturated fat intake increases the 
predisposition of osteoporotic fractures in elderly patients [270]. However, the complexity 
involved in categorizing the type of dietary fat intake in human subjects complicates data 
collection and might explain for the lack of literature.  
As a pilot study, we intend to delineate possible differences between different fat types and its 
effects on bone homeostasis. We explored the effects of the various C18 fat molecules: 
stearic acid (SA; saturated), oleic acid (OA; non-saturated) and elaidic acid (EA; trans). 
Using different sources of fat as a model to understand how the excess intake of fat can affect 
other bone homeostasis, we briefly challenged age-matched mice to 15% fat: 85% grounded 
chow (w/w) for 8 days and recorded for any morphological alterations on the tibia. Scanning 
electron micrographs reveal that the tibia of fat-challenged mice exhibited a range of 
depressions and grooves on the bone surface, while the bone matrix formed irregular pits 
when compared to mice on normal diet (Figure 5.2a). Preliminary findings reveal that 
connective tissue disorders, organismal injury and abnormalities as well as skeletal and 
muscular disorders are amongst the top disease functions mapped for fat challenge. 
Interestingly, we observed a brief increase in TNF and TGFβ1 expression in both EA and SA 
but not OA challenge (Figure 5.2b), suggesting that both an increase in trans and saturated 
fat intake might attribute to the chronic inflammatory phenotype associated to high fat diet 
observed in several population-based correlative studies. We also observed that the most 
significant disease associated to an increase in fat diet relates to bone homeostasis: 
osteoporosis, abnormal bone density and size, as well as skeletal and connective tissue 
morphology. 
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Figure 5.2 Dietary long chain fatty acid and bone homeostasis. (a) Scanning electron micrographs 
showing the surface (upper panel) and matrix of mouse tibia, isolated from age-matched mice 
challenged with EA, SA or OA. (b)Microarray gene expression analysis of colon samples of mice 
challenged with EA, SA or OA versus Veh. Transcripts were estimated using a log2 transformation and 
later subjected to unbiased ANOVA to identify gene clusters that are differentially expressed 
between challenge groups. Only genes that recorded fold changes <-1.2 or >1.2 were of significance. 
Connective tissue disorders, organismal injury and abnormalities and skeletal and muscular disorders 
ranks top spots in correlation to diseases commonly associated with changes in gene expression, 
with corresponding up-regulated or down-regulated genes in red or green. Scale bar = 10 µm.  
 
In this respect, authors of population-based cohort studies once reasoned that bone mineral 
density could be a more appropriate predictor of mortality compared to other prominent 
markers like cholesterol and blood pressure [271, 272]. Although purely epidemiological, it 
was found that menopausal women were less likely to lose significant amount of bone mass 
and develop osteoporosis if they possessed a higher body fat mass [273, 274]. Osteoporosis is 
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a disease characterized by decreased bone density, mass and strength, causing skeletal 
fragility. Since the density of bone mass depended on a fine balance between bone formation 
by osteoblasts and bone resorption by osteoclasts, this observation suggests a potential 
homeostatic loop between the bone-adipose axis. To date, Gomez-Ambrosi et al suggested an 
active glucose homeostasis crosstalk through proteins like osteocalcin and osteopontin that 
are secreted by bone cells that could impact adipocyte signaling by augmenting circulating 
adiponectin and insulin [275, 276]. However, intimate signaling pathways within the bone-
adipose axis remains to be elucidated. 
Quite recently, Shafik et al and Li et al reported that ANGPTL4 exerts its effects through IL-
1β and NF-κB in breast cancer [277], as well as through IL-6-Stat3 signaling in influenza 
[229]. However, the identities of other regulatory proteins involved in the ANGPTL4-
dependent signaling axis remains to be elucidated. On the other hand, independent groups 
have previously characterized TTP for its role in regulating mRNA transcript stability of a 
subset of cytokines, and so, have extensively demonstrated that TTP acts as a molecular 
switch to allow cells to respond quickly to external stimuli during acute inflammation. 
Despite the wealth of accumulated literature generated by independent laboratories, there has 
not been much known between environmental sensor proteins like ANGPTL4 and an 
intermediate, fast-response switch like TTP that has been implicated in the plethora of 
diseases.  
TAMs in close proximity of the pro-inflammatory tumor microenvironment are believed to 
play key roles in incubating the growing tumor [278, 279]. The plasticity of macrophages 
allows them to be further polarized into pro-inflammatory M1 or anti-inflammatory M2 states 
as a response to environmental stimuli [280, 281]. However, it was reported that TAMs 
predominantly adopt M2 polarized states [282, 283], promoting a muted immune response 
essential for immune-suppression around the tumor site. Interestingly, Schumann et al 
demonstrated that TAMs express high levels of ANGPTL4 [284] while Schmid et al 
suggested that patients with elevated C-reactive protein (CRP) levels had a worsened 
prognosis [285]. Wu et al, Waschki et al and Tjeerdema et al later found that ANGPTL4 
share a close relationship with CRP during chronic obstructive pulmonary disease [286, 287] 
and type II diabetes [230]. Hersoug et al also reported that gut microbial-derived LPS 
increases chylomicron transport in the lymph circulation, promoting fat absorption and also 
macrophage M2 to M1 polarization [288]. However, the relationship between ANGPTL4 and 
macrophage polarization involved in tumor proliferation, migration and the EMT process 
remains largely unclear.  
In conclusion, novel findings brought forth in this thesis describes the multi-faceted role of 
ANGPTL4, drawing links between the external environment, commensal microbiota, host 
metabolic and immune systems that determine the parameters for health or illness.  
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